MWB Research keeps EUR 135 target for DrÀgerwerk stock
Published on 10/26/2026 at 10:13 | Editorial responsibility: Rafael MĂŒller, Editor-in-Chief AD HOC NEWSGrowth meets a margin test
- MWB Research kept its EUR 135.00 target on October 15, 2026.
- DrÀger reported a 6.00 to 8.00 percent EBIT margin outlook for fiscal year 2026.
- DrÀgerwerk stock trades at EUR 100.90 at 10:06 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.30 percent above the Xetra close of October 23, 2026.
- The next quarterly report is scheduled for October 29, 2026.
- Market capitalization stood at EUR 1.9 billion as of October 26, 2026.
DrÀgerwerk (ISIN DE0005550636) was trading at EUR 100.90 at Lang & Schwarz on October 26, 2026, at 10:06 a.m. CEST, plus 0.30 percent versus the Xetra close of October 23, 2026 at EUR 100.60. ResearchHub reported on October 15, 2026 that MWB Research kept its EUR 135.00 price target and Buy rating after DrÀger's preliminary third-quarter figures.
Q3 profit exposes cost pressure
According to Deutsche Boerse, DrÀger generated EBIT of EUR 48.00 million in the third quarter of 2026, down from EUR 56.70 million in the third quarter of 2025. The result included EUR 20.10 million of customs-duty refunds, while revenue rose 2.10 percent to EUR 851.00 million.
What does the margin gap mean?
The reported EBIT margin was 5.60 percent in the third quarter of 2026, below the company's fiscal-year 2026 target range of 6.00 to 8.00 percent. Cost growth therefore matters more than the headline sales increase, although the Safety Technology division helped: its third-quarter revenue rose 5.30 percent nominally to EUR 381.00 million, while Medical Technology revenue fell 0.40 percent to EUR 469.00 million.
Three dated events explain the setup
On October 9, 2026, ResearchHub reported that MWB Research raised its target from EUR 130.00 to EUR 135.00 after the FDA warning letter was lifted. On October 14, 2026, Deutsche Boerse published preliminary figures showing the lower EBIT. On October 15, 2026, MWB Research kept the EUR 135.00 target and Buy rating, according to ResearchHub.
Two dates matter next
DrÀger scheduled publication of its third-quarter 2026 report for October 29, 2026, followed by a conference call. The company also scheduled its Capital Markets Day for November 18, 2026.
Stock remains below its yearly high
At EUR 100.90, DrÀgerwerk stock was 19.54 percent below its 52-week high of EUR 125.40 and above its 52-week low of EUR 66.00 on October 26, 2026. Market capitalization was EUR 1.9 billion on that date. The further course of trading is shown by the continuously updated real-time quote of DrÀgerwerk stock.
DrÀgerwerk stock facts
- Company: DrÀgerwerk AG & Co. KGaA
- ISIN: DE0005550636
- WKN: 555063
- Ticker: DRW3
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 26, 2026, 10:06 a.m. CEST): EUR 100.90
- Change versus Xetra close: plus 0.30 percent
- Xetra close (October 23, 2026): EUR 100.60
- Market capitalization: EUR 1.9 billion (as of October 26, 2026)
- 52-week range: EUR 66.00-125.40 (as of October 26, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Index membership: SDAX and TecDAX
- Next earnings date: October 29, 2026
Market context: Market report DAX.
